HC Wainwright Issues Negative Outlook for PolyPid Earnings

PolyPid Ltd. (NASDAQ:PYPD) – Investment analysts at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for PolyPid in a research note issued on Monday, April 14th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.80) per share for the quarter, down from their prior forecast of ($0.74). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.42) EPS and FY2025 earnings at ($1.87) EPS.

PYPD has been the subject of a number of other reports. Rodman & Renshaw started coverage on PolyPid in a report on Tuesday, January 28th. They set a “buy” rating and a $13.00 price objective for the company. RODMAN&RENSHAW raised shares of PolyPid to a “strong-buy” rating in a report on Tuesday, January 28th.

PolyPid Price Performance

PYPD opened at $2.70 on Wednesday. The company has a fifty day simple moving average of $2.82 and a 200 day simple moving average of $3.09. PolyPid has a 12 month low of $2.30 and a 12 month high of $5.09. The company has a quick ratio of 1.00, a current ratio of 1.31 and a debt-to-equity ratio of 0.08. The stock has a market cap of $27.52 million, a P/E ratio of -0.54 and a beta of 1.28.

PolyPid (NASDAQ:PYPD) last posted its earnings results on Wednesday, February 12th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.23).

Institutional Investors Weigh In On PolyPid

A number of large investors have recently bought and sold shares of the company. Rosalind Advisors Inc. boosted its holdings in shares of PolyPid by 50.6% during the 4th quarter. Rosalind Advisors Inc. now owns 1,022,521 shares of the company’s stock valued at $3,108,000 after acquiring an additional 343,353 shares in the last quarter. AIGH Capital Management LLC raised its holdings in shares of PolyPid by 21.8% during the fourth quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock valued at $2,509,000 after purchasing an additional 148,199 shares during the period. Finally, J. Goldman & Co LP acquired a new stake in PolyPid in the 4th quarter valued at $391,000. 26.47% of the stock is currently owned by institutional investors and hedge funds.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.